PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 8, 2026Frontiers in Cardiovascular Medicine1 citationsOpen Access

Lipoprotein(a) and plaque progression: insights from serial coronary computed tomography angiography and quantitative plaque assessment

KHKunhui HuangBeihang UniversityYZYonghong ZhengFujian Provincial HospitalSWSiying WuYunnan Provincial Department of Education

Key Points

  • The aim is to explore the relationship between Lp(a) levels and coronary plaque characteristics.
  • Retrospective analysis of patients with baseline and follow-up coronary computed tomography angiography.
  • Categorized patients into elevated and normal Lp(a) groups based on levels.
  • Quantitative assessments measured various plaque characteristics and progression.
  • Elevated Lp(a) linked to higher baseline plaque burden.
  • Accelerated plaque volume progression observed in patients with elevated Lp(a).
  • Specific subgroups, such as those with diabetes or under 60, demonstrated higher plaque progression rates.

Abstract

Background Lipoprotein(a) Lp(a) is a well-established independent risk factor for cardiovascular disease. However, the long-term effects of Lp(a) on coronary plaque phenotype remain unclear. Objective To explore the potential association between Lp(a) levels and coronary plaque volume, composition, and progression using coronary computed tomography angiography (CCTA). Methods Patients with available data for Lp(a) and underwent baseline CCTA examinations between January 2009 to December 2015 and subsequently underwent a follow-up coronary CTA were retrospectively enrolled. Quantitative CCTA analyses measured plaque length, total plaque volume and composition volume. Patients were categorized into an elevated Lp(a) group (≥30 mg/dL) and a normal Lp(a) group (30 mg/dL). The association between Lp(a) and baseline plaque characteristic and progression were investigated in linear mixed-effects models adjusted for clinical factors. Subgroup analyses were also conducted. Results Among 453 patients (mean age 64.7 years, 77.7% male) with a median follow-up of 6.15 years. elevated Lp(a) was linked to higher baseline plaque burden (all p 0.001) and accelerated LAP volume progression ( β = 0.55 mm 3 /year, 95% CI: 0.04–1.06; p = 0.036) after adjusting for confounders. In addition, patients with diabetes, female gender, family history of CAD, or aged 60 years and with normal lipid profiles showed higher progression in total plaque volume and LAP, fibro-fatty, and fibrous components. Increased calcification volume progression was also seen in those with diabetes, female gender, smoking, drinking, or normal LDL-C levels. The association between Lp(a) and calcification progression was more pronounced in statin users. Conclusions Elevated Lp (a) level was associated with high coronary artery plaque burden at baseline and rapid progression of LAP at follow-up. Lp(a) may serve as a significant residual risk factor in seemingly “low-risk” populations.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Huang et al. (2026) studied this question.

synapsesocial.com/papers/698827a20fc35cd7a88468d7https://doi.org/10.3389/fcvm.2026.1699503
Ask AI
Helpful
Bookmark
Share
View Full Paper